A long-standing collaboration between UNSW researchers and Inventia Life Science is helping advance 3D bioprinting technologies while creating pathways for researchers to apply materials science to disease modelling, drug development and wound healing.
As an undergraduate chemistry student, Yi Pei was intrigued by colourful images from zebrafish research, which uses the fish to study genetics, human diseases and potential drug treatments.
She approached a professor hoping to work with the small fish but was told animal experiments might be too complex for an undergraduate. The professor suggested she begin with a more manageable project: designing and making short chains of amino acids called peptides.
Yi soon learned that these molecules could be used to deliver drugs and create gels that mimic aspects of human tissue. This was her first introduction to biomaterials, and the beginning of her interest in using materials science to address medical challenges.
Her studies have set her on a career path that has taken her from China and the United States to UNSW Sydney, and now into the biotechnology industry.
Today, she is a Senior Scientist in Research and Development at Sydney-based life science tools company, Inventia Life Science, where she is helping develop technology that could one day be used to support wound healing and tissue regeneration.
Her career journey is one example of the pathways created through Inventia’s ongoing collaborations with UNSW researchers. These collaborations helped develop the RASTRUM 3D bioprinter, which creates three-dimensional cell and tissue models for disease research and drug development.
From materials science to bioprinting
Yi began her PhD at the University of Illinois before moving to Australia to study with Professor Kristopher Kilian in 2018. At UNSW, she completed her PhD in Materials Science and Engineering, developing expertise in biomaterials and tissue engineering.
“I was keen to see the other side of the world,” Yi says. “I had the opportunity to learn about a different country, a different culture and a different research culture.”
Her research background proved a strong match for Inventia’s work. The company develops desktop bioprinters, software and biomaterials that can be used to create three-dimensional cell models for research, including models that can help scientists study disease and screen potential drugs.
“When I applied for my current job, they mainly looked at my research background and it matched very well,” Yi says. “There was a very big overlap between what I had done in Professor Kilian’s lab and what Inventia was interested in doing.”
UNSW’s longstanding collaboration with Inventia has brought researchers from the University and company together to develop and refine 3D bioprinting technologies. It has also created a shared understanding of the materials science and tissue-engineering expertise needed to move the technology forward.
Yi was a natural fit for Inventia’s research team, and other researchers from Prof. Kilian’s lab have since taken up positions at the company.
“Yi is using the materials chemistry skills she developed to design new biomaterial inks for drug development and 3D-printed skin. She’s contributed to both,” Prof. Kilian says.
Jason Leavens, Head of Research and Development for LIGŌ at Inventia, says, “Taking bioprinting into the clinic needs people who understand materials chemistry, cell biology and engineering at once, and that combination is rare.
“Yi brought exactly that from Professor Kilian’s lab. Her UNSW training meant she contributed from day one, and she has become one of the key scientists behind the biomaterial inks we’re developing to print directly into wounds.”
Technology to support wound healing and tissue regeneration
At Inventia, Yi works in a group developing a system that combines the company’s bioprinting technology with a robotic arm. Unlike Inventia’s RASTRUM system, which prints cell models into well plates for research, the new system (LIGŌ) is being designed to print biomaterials and cells directly into wounds.
Her work focuses on developing and testing the biomaterials, or “inks”, used by the system. These materials need to support cell growth and be suitable for use in the body.
The longer-term goal is to develop a system that could support wound healing and tissue regeneration, including for people with severe burns or other tissue damage.
“There are a lot of pieces in the whole workflow,” Yi says. “You need cells from the patient, biomaterials and a printer that can be safely used to put the construct back into the patient.”
Using a patient’s own cells is important because the body can reject cells from another person or an animal, triggering an immune response.
Inventia has completed a first-in-human clinical trial at Concord Repatriation General Hospital to assess the feasibility and safety of LIGŌ. In the study, cells were collected from patients, incorporated into the bioink and printed into their wounds.
“It makes me feel fantastic that the people I’ve mentored are now working on projects that can go into clinical trials and improve human health,” Prof. Kilian says.
Yi says seeing research develop into something that other people could use has been particularly rewarding.
“It’s very rewarding to see what you worked on turn into something that other people could use,” she says.
Yi Pi has a PhD in Materials Science and Engineering (UIUC) with research completed at UNSW as a visiting scholar, 2019.